We are excited to welcome new Bio Nebraska member, Mopac Biologics.
Mopac Biologics is developing best-in-class oral and topical biologic therapies for autoinflammatory diseases. Mopac uses computational protein design technology originating at the University of Washington that uniquely enables discovery of therapeutics with desirable properties, including extremely high potency and resistance to gastrointestinal conditions. With their drug discovery capabilities and world-class development team, Mopac aims to bring safe, effective, and convenient therapies to the clinic. Their lead molecule, MB1, is an oral protein inhibitor of IL-23R in preclinical development for treatment of Inflammatory Bowel Disease.